Novo Nordisk Partners with OpenAI to Integrate AI in Drug Discovery and Manufacturing

# Novo Nordisk Partners with OpenAI on AI for Pharmaceuticals Danish pharmaceutical company Novo Nordisk announced on Tuesday that it was teaming up with OpenAI to integrate artificial intelligence across drug discovery, manufacturing, and commercial activities. The announcement comes after some companies began utilizing AI platforms for drug discovery in February 2025.

participated in an event on “Making Health Technology Great Again,” in the East Room of the White House in Washington, D.C., on July 30, 2025. The Centers for Medicare and Medicaid Services announced in July 2025 a new effort to create a digital health ecosystem alongside several technology firms to improve patient outcomes and reduce provider burden.

and Action Plan U.S.

President Donald Trump announced in March a new national legislative framework for AI, stating his administration is committed to winning the AI race to usher in a new era of human flourishing, economic competitiveness, and national security for the American people.

President Donald Trump unveiled an AI action plan in July 2025 aiming to usher in a new Golden Age of innovation, human flourishing, and technological achievement for the American people.

An American Medical Association’s Center for Digital Health and AI survey released in March found that 81% of physicians utilized AI in their practices, up from 38% in 2023.

The survey showed that the most common use of AI among physicians was medical research summarization and clinical care documentation.

in Health Care Jeffrey Singer, a senior fellow at the Cato Institute and president emeritus and founder of Valley Surgical Clinics Ltd, told the DCNF that the expansion of AI could lower health care costs, increase affordability, and expand patient autonomy.